Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE W CODEINE versus TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE W CODEINE versus TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES.
PROMETHAZINE W/ CODEINE vs TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, which inhibits nociceptive transmission; promethazine is a phenothiazine derivative with H1-receptor antagonism, anticholinergic, and antiemetic effects.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.
10 mL (1 mg codeine, 6.25 mg promethazine per 5 mL) orally every 4-6 hours as needed for cough. Maximum: 60 mL per day. Do not exceed 5 days.
1 capsule (triprolidine 2.5 mg/pseudoephedrine 60 mg) orally every 4-6 hours; not to exceed 4 doses in 24 hours.
None Documented
None Documented
Promethazine: 10-19 hours (terminal). Codeine: 2.5-3.5 hours (terminal); prolonged in renal impairment.
Triprolidine: 5-7 hours. Pseudoephedrine: 4-8 hours (pH-dependent; alkaline urine prolongs half-life). Clinical context: Dose adjustment needed in renal impairment for pseudoephedrine.
Promethazine: renal (70% as metabolites, <1% unchanged), fecal (20-30%). Codeine: renal (90%, of which 5-10% unchanged, rest as metabolites), fecal (minor).
Triprolidine: Renal excretion of metabolites (approx. 60%) and unchanged drug (less than 5%). Pseudoephedrine: Primarily renal elimination as unchanged drug (70-90%), with minor hepatic metabolism. Fecal excretion is negligible for both.
Category A/B
Category A/B
Antihistamine / Antiemetic
Antihistamine